IMMP

Business Context and Reporting Period

Company: Immutep Ltd (ASX: IMM, NASDAQ: IMMP)
Reporting Period: Fiscal Year ended June 30, 2025 (FY2025)
Business Overview: Immutep is a late-stage biotechnology company developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases. The company has no approved products for commercial sale and generates no material product revenue. Its primary focus is the clinical development of its lead candidate, eftilagimod alfa ("efti"), and other pipeline assets including IMP761 (autoimmune), IMP701 (licensed to Novartis), and IMP731 (returned from GSK).

Key Financial Metrics

Note: All figures are in Australian Dollars (A$). The increase in Total Other Income was driven by higher interest income (A$5.3m vs A$3.9m) and grant income (A$5.0m vs A$3.7m), partially offset by a net foreign exchange loss of A$1.5 million.

Material Changes vs. Prior Period

• Increased Burn Rate: The net loss widened by A$18.7 million to A$61.4 million, primarily due to a significant increase in R&D expenses (A$19.9 million increase) driven by the advancement of clinical trials, specifically the initiation of the pivotal Phase III TACTI-004 trial in non-small cell lung cancer (NSCLC).
• Cash Position: Total cash and short-term investments decreased by approximately A$52 million. While the company raised A$100.2 million in equity in June 2024, the high operational burn rate and increased investment in term deposits (classified as short-term investments) resulted in a lower net cash balance compared to the prior year-end.
• Foreign Exchange: The company recorded a net foreign exchange loss of A$1.53 million in FY2025, compared to a net gain of A$0.11 million in FY2024, due to currency fluctuations.
• Grant Income: Grant income increased to A$4.97 million, reflecting the recognition of the French Crédit d'Impôt Recherche scheme and Australian R&D tax incentives.

Guidance, Outlook, and Management Commentary

• Clinical Milestones:
  • TACTI-004 (Phase III NSCLC): Initiated in December 2024 with the first patient dosed in March 2025. This is a registrational trial evaluating efti in combination with anti-PD-1 therapy and chemotherapy in 1st line NSCLC.
  • TACTI-003 (Phase IIb HNSCC): Completed enrollment. Positive data reported in July and September 2024 showed efficacy in PD-L1 negative patients. Mature OS data reported in May 2025 showed a median OS of 17.6 months in the PD-L1 negative cohort.
  • AIPAC-003 (Phase II/III Breast Cancer): Phase II portion completed in October 2024. FDA feedback received in October 2025 confirmed 30mg as the optimal biological dose.
  • IMP761 (Autoimmune): Phase I first-in-human study initiated in August 2024. Initial pharmacological data in June 2025 showed significant T cell suppression and a favorable safety profile.
• Liquidity Outlook: Management anticipates that current cash and cash equivalents (A$129.7 million) will be sufficient to fund operations at least until the end of calendar year 2026. However, the company expects to require substantial additional funds to achieve long-term goals and may need to raise further capital.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing, reliance on third-party manufacturers, and potential foreign exchange volatility. The company has no medicinal products approved for commercial sale.

Important Facts for Investors to Verify

• Cash Runway: Verify the sufficiency of the A$129.7 million liquidity position against the projected burn rate for the ongoing Phase III TACTI-004 trial and other development programs through 2026.
• TACTI-004 Progress: Monitor patient enrollment rates and interim data readouts for the pivotal Phase III NSCLC trial, which is critical for potential regulatory approval.
• Capital Raising Needs: Assess the likelihood and timing of future equity or debt financing required to sustain operations beyond late 2026, given the company's history of operating losses.
• Collaboration Dependencies: Review the status of collaborations with Merck & Co. (MSD) for TACTI-004 and TACTI-003, and the potential for milestone payments or royalty revenues from partners like Novartis (IMP701) and EOC Pharma (China rights).
• Foreign Exchange Exposure: Evaluate the impact of AUD/USD and AUD/EUR fluctuations on future operating costs, as the company has significant expenses denominated in foreign currencies.